吸入性皮质类固醇-长效β-2激动剂固定剂量组合:在6至11岁患有持续性喘的儿童中,首选的控制器
Gizem Koken1, Sinem Polat Terece2, Ceren Varer Akpinar3
1Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Turkey, kokengizem@gmail.com.
International archives of allergy and immunology
|March 4, 2025
概括
吸入性皮质类固醇和长效β-2agonist (ICS-LABA) 的组合比单独的ICS更有效地预防6-11岁儿童的喘恶化. 这些固定剂量组合被推作为持续性喘的首选控制剂.
科学领域:
- 儿科肺病学 儿科肺病学
- 喘管理 喘管理
- 药物治疗 药物治疗
背景情况:
- 6-11岁儿童的持久性喘缺乏直接比较的数据,比如吸入性皮质类固醇 (ICS) 单疗法和ICS-长效β-2agonist (ICS-LABA) 固定剂量组合.
- 目前的治疗指南将儿童置于2至4阶段,有不同的控制器选择.
研究的目的:
- 为了比较ICS单疗与ICS-LABA固定剂量组合疗法的疗效,在6-11岁儿童中减少需要全身皮质类固醇 (CS) 的喘恶化.
- 为了评估控制器药物在治疗儿科患者持久性喘的有效性.
主要方法:
- 从2021年1月到2024年1月,回顾性分析了6至11岁的患有持续性喘的儿童的电子健康记录,这些儿童接受了含有ICS的治疗 (流动 propionate [FP],流动 propionate/salmeterol [FP/SAL],布德索尼德/formoterol [BUD/F]).
- 收集的数据包括喘控制药物,恶化的频率 (需要全身CS,ED访问或住院治疗),以及肺炎发病率.
主要成果:
- 与ICS单独治疗 (FP) 相比,ICS-LABA固定剂量组合 (FP/SAL,BUD/F) 显示所有恶化,需要CS的恶化和ED访问/住院恶化的频率明显较低.
- 对于任何恶化参数,FP/SAL和BUD/F组之间没有发现显著差异.
- 固定剂量组合组的肺炎发病率较低,不允许进行统计比较.
结论:
- 在预防6至11岁儿童喘恶化方面,ICS-LABA固剂组合疗法比ICS单一疗法更有效.
- 这些组合疗法代表了在这种儿科患者群体中管理持久性喘的首选控制者选择.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
201
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
201
COPD: Management Using Bronchodilators and Corticosteroids
170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170
Inhaled Medications
218
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
218
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Leukotriene Modifiers
230
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
230
Antiasthma Drugs: β2-Adrenoceptor Agonists
224
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
224


